A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-07. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Operation Protea had exposed a glaring lack of professionalism on the part of FAPLA units, which had relied too heavily on their Soviet advisers and were almost immediately routed once they had to leave their fortified bases. In terms of training, morale, organisation, and professional competence—including the ability to operate its own equipment with effectiveness—the Angolan army had proved decidedly vulnerable. Protea indicated that it was in no condition to repel or even inflict serious losses on the South African expeditionary troops, resulting in a ratio of casualties almost overwhelmingly in the SADF's favour. That debacle led to a greater FAPLA dependency on augmented Cuban forces and another large arms deal, valued in excess of one billion dollars, being signed with the Soviet Union. Defence expenditures increased to consume 50% of Angola's state budget by the end of 1982. FAPLA embarked on a massive recruiting drive, purchased new T-54/55 and T-62 tanks from the Soviet Union, and took delivery of about thirty new combat aircraft, including twelve Sukhoi Su-20 strike fighters. It also ordered more air search radars and surface-to-air missiles to replace those destroyed in Protea. While Namibianisation altered the tactical realities of the war on the Cutline, the SADF was planning a fourth operation modelled after Sceptic, Protea, and Daisy. In April 1982, PLAN insurgents killed 9 South African soldiers near Tsumeb, over 200 kilometres south of the border.
Morpholino Also phosphorodiamidate Morpholino oligomer. A synthetic nucleic acid analogue connecting a short sequence of nucleobases into an artificial antisense oligomer, used in genetic engineering to knockdown gene expression by pairing with complementary sequences in naturally occurring RNA or DNA molecules, especially mRNA transcripts, thereby inhibiting interactions with other biomolecules such as proteins and ribosomes. Morpholino oligomers are not themselves translated, and neither they nor their hybrid duplexes with RNA are attacked by nucleases; also, unlike the negatively charged phosphates of normal nucleic acids, the synthetic backbones of Morpholinos are electrically neutral, making them less likely to interact non-selectively with a host cell's charged proteins. These properties make them useful and reliable tools for artificially generating mutant phenotypes in living cells.
== Etymology == The name derives from the Ancient Greek word πολύς (polus, meaning "many, much") and the word 'phenol' which refers to a chemical structure formed by attachment of an aromatic benzenoid (phenyl) ring to a hydroxyl (-OH) group (hence the -ol suffix). The term "polyphenol" has been in use at least since 1894.
== Enzyme Structure and Structural studies == Structurally, haloalkane dehalogenases belong to the alpha/beta-hydrolase superfamily. Their active site is buried in a predominantly hydrophobic cavity at the interface of the alpha/beta-hydrolase core domain and the helical cap domain, and is connected to the bulk solvent by access tunnels. The active-site residues that are essential for catalysis are referred to as the catalytic pentad, and comprise a nucleophilic aspartate residue, a basic histidine residue, an aspartic or glutamic acid moiety that serves as a general acid and either two tryptophan residues or a tryptophan-asparagine pair that serve to stabilize the leaving halide ion. The haloalkane dehalogenase family currently includes 14 distinct enzymes with experimentally confirmed dehalogenation activity. An analysis of the sequences and structures of haloalkane dehalogenase and their homologues divided the family into three subfamilies, which differ mainly in the composition of their catalytic pentad and cap domain. As of late 2007, 25 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1B6G, PDB: 1BE0, PDB: 1BEE, PDB: 1BEZ, PDB: 1BN6, PDB: 1BN7, PDB: 1CIJ, PDB: 1CQW, PDB: 1CV2, PDB: 1D07, PDB: 1EDB, PDB: 1EDD, PDB: 1EDE, PDB: 1HDE, PDB: 1K5P, PDB: 1K63, PDB: 1K6E, PDB: 1MJ5, PDB: 2DHC, PDB: 2DHD, PDB: 2DHE, PDB: 2EDA, PDB: 2EDC, PDB: 2PKY, and PDB: 2YXP.
==== Swearing-in ceremony controversy ==== On 1 January 2025, Melo and his vice-mayor, Betina Worm of the Liberal Party (PL), took office during the swearing-in ceremony of the Municipal Chamber of Porto Alegre as the city council members were also sworn in. Melo generated controversy by stating that "defenders of the Brazilian military dictatorship should not be prosecuted because this would represent freedom of expression", and also affirmed that "defenders of socialism and communism do not deserve to be punished." Opposition parties would go on to publicly protest against Melo for these comments.
Sources: en.wikipedia.org
The ionic nature of proteins was demonstrated by Bjerrum, Weber and Arne Tiselius, but Linderstrom-Lang showed that the charges were generally accessible to solvent and not bound to each other (1949). The secondary and low-resolution tertiary structure of globular proteins was investigated initially by hydrodynamic methods, such as analytical ultracentrifugation and flow birefringence. Spectroscopic methods to probe protein structure (such as circular dichroism, fluorescence, near-ultraviolet and infrared absorbance) were developed in the 1950s. The first atomic-resolution structures of proteins were solved by X-ray crystallography in the 1960s and by NMR in the 1980s. As of 2019, the Protein Data Bank has over 150,000 atomic-resolution structures of proteins. In more recent times, cryo-electron microscopy of large macromolecular assemblies has achieved atomic resolution, and computational protein structure prediction of small protein domains is approaching atomic resolution.
== Role in disease == A defect in the degradation of glucocerebrosides is Gaucher's disease. The corresponding defects for galactocerebrosides are: a) Ceramide trihexoside (globotriaosylceramide) accumulation – Fabry's disease. Clinical features include acroparaesthesia (tingling, pins and needles sensation in the extremities) b) Galactocerebroside (galactosylceramidase) accumulation – Krabbe disease.
Angiotensin I (CAS# 11128-99-7), officially called proangiotensin, is formed by the action of renin on angiotensinogen. Renin cleaves the peptide bond between the leucine (Leu) and valine (Val) residues on angiotensinogen, creating the decapeptide (ten amino acid) (des-Asp) angiotensin I. Renin is produced in the kidneys in response to renal sympathetic activity, decreased intrarenal blood pressure (<90 mmHg systolic blood pressure ) at the juxtaglomerular cells, dehydration or decreased delivery of Na+ and Cl- to the macula densa. If a reduced NaCl concentration in the distal tubule is sensed by the macula densa, renin release by juxtaglomerular cells is increased. This sensing mechanism for macula densa-mediated renin secretion appears to have a specific dependency on chloride ions rather than sodium ions. Studies using isolated preparations of thick ascending limb with glomerulus attached in low NaCl perfusate were unable to inhibit renin secretion when various sodium salts were added but could inhibit renin secretion with the addition of chloride salts. This, and similar findings obtained in vivo, has led some to believe that perhaps "the initiating signal for MD control of renin secretion is a change in the rate of NaCl uptake predominantly via a luminal Na,K,2Cl co-transporter whose physiological activity is determined by a change in luminal Cl- concentration." Angiotensin I appears to have no direct biological activity and exists solely as a precursor to angiotensin II.
==== Energy policies ==== In his 2006 State of the Union Address, Bush declared, "America is addicted to oil" and launched his Advanced Energy Initiative to increase energy development research. In his 2007 State of the Union Address, Bush renewed his pledge to work toward diminished reliance on foreign oil by reducing fossil fuel consumption and increasing alternative fuel production. Amid high gasoline prices in 2008, Bush lifted a ban on offshore drilling. However, the move was largely symbolic because there was still a federal law banning offshore drilling. Bush said: "This means that the only thing standing between the American people and these vast oil reserves is action from the U.S. Congress." Bush had said in June 2008, "In the long run, the solution is to reduce demand for oil by promoting alternative energy technologies. My administration has worked with Congress to invest in gas-saving technologies like advanced batteries and hydrogen fuel cells ... In the short run, the American economy will continue to rely largely on oil. And that means we need to increase supply, especially here at home.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.